1-3 of 3
Edgar Braendle, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Claudia Lebedinsky, MD, Stephen P. Anthony, DO, Golam Mohi, PhD, Huyuan Yang, PhD, Jian Mei, PharmD, Edgar Braendle, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-134039
Published: 2020
Journal Articles

Molecular Testing for Response to Treatment for Chronic Myeloid Leukemia (CML) Patients: Information Available to Decision Makers on the Costs and Analytical and Clinical Validity of Alternative Approaches.

Edgar Braendle, MD, PhD, Peter Hudson, M.Sc, Ossa Diego, Ph.D, Ratcliffe Mark, Ph.D
Journal: Blood
Blood (2010) 116 (21): 4489.
https://doi.org/10.1182/blood.V116.21.4489.4489
Published: 2010
Journal Articles

Serum Concentrations of DKK-1 Correlate with the Extent of Bone Disease in Multiple Myeloma.

Martin Kaiser, MD, Maren Mieth, PhD, Peter Liebisch, MD, PhD, Susanne Rötzer, Christian Jakob, MD, Claudia Fleissner, MD, Edgar Braendle, MD, PhD, David Stover, PhD, Malte Peters, MD, PhD, Orhan Sezer, MD, PhD, Ulrike Heider, MD
Journal: Blood
Blood (2007) 110 (11): 3518.
https://doi.org/10.1182/blood.V110.11.3518.3518
Published: 2007